INTELLIGENT BIO SOLUTIONS INC. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Intelligent Bio Solutions reported fiscal 2026 (year ended June 30, 2026) revenue of $4.215M (+38% YoY from $3.053M), driven by 22% growth in reader installed base (1,886 units) and 35% growth in consumable cartridges (106,500 units). Gross profit jumped 64% to $2.050M with margin expanding 778 basis points to 48.63%, attributed to manufacturing transition to Syrma Johari and product mix optimization. The company completed FDA 510(k) clinical data collection and remains on track for H2 2026 submission targeting U.S. drug screening market entry; active customers reached 502 and a strategic partnership with Bouygues UK was secured.
Why this rating
Strong revenue/margin growth and FDA pathway clarity are material for a $6.6M-market-cap company; $4.2M revenue represents meaningful scale-up. Yet $12.4M net loss, pre-FDA approval risk, and narrow operating runway temper trajectory change potential.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.